Fig. 4

Correlation of tumoral CCR7 expression and patients’ baseline and post-administration lymphatic involvements. a Tumoral CCR7 expression according to different patient baseline metastatic sites; b Four mRCC patients who have experienced disease progression due to new lymphatic lesions development after tyrosine kinase inhibitors, all with high CCR7 expression. White arrow: the area where new lymph node lesions developed during administration